JNJ

5 Defining Moments from Some of the Top 100 Medical Device Companies
Medical Devices and Diagnostics Industry
Wed, 06/4/25 - 11:01 am
Medtech
Holologic
Cynosure
Boston Scientific
M&A
Abbott Labs
Alere
JNJ
Verb
Medtronic
PFA
ASCO: Sanofi shows investigational Sarclisa SC, delivered by on-body device, measures up to its IV formulation
Fierce Pharma
Tue, 06/3/25 - 11:39 am
Sanofi
Sarclisa SC
JNJ
Darzalex
ASO 2025
Multiple Myeloma
ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups
Clinical Trials Arena
Mon, 06/2/25 - 11:15 am
ASCO 2025
JNJ
Carvykti
cell therapy
Multiple Myeloma
ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug
Clinical Trials Arena
Mon, 06/2/25 - 11:09 am
JNJ
clinical trials
ASCO 2025
pasritamig
bispecific antibodies
metastatic castration-resistant prostate cancer
Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change
Pharma Voice
Tue, 05/27/25 - 11:10 am
Pharma CEOs
Novo Nordisk
JNJ
AbbVie
Merck
pharma industry
J&J's Darzalex wins FDA advisors' backing as potential first treatment for smoldering myeloma
Fierce Pharma
Wed, 05/21/25 - 11:33 am
JNJ
Darzalex
Multiple Myeloma
FDA
J&J Faces $147M Antitrust Verdict in Catheter Case
Medical Devices and Diagnostics Industry
Tue, 05/20/25 - 09:49 pm
JNJ
antitrust
Medtech
legal
Weighing approval bids from J&J, Pfizer and Roche, FDA scrutinizes data ahead of adcomm
Fierce Pharma
Sun, 05/18/25 - 10:33 pm
FDA
JNJ
Pfizer
Roche
cancer
accomm
J&J, Eli Lilly join $85M financing for newly unveiled gene editing biotech Stylus
Fierce Biotech
Tue, 05/13/25 - 11:10 am
Stylus Medicine
funding
JNJ
Eli Lilly
gene editing
Johnson & Johnson (JNJ) reports Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
Marketscreener
Fri, 05/9/25 - 08:59 am
JNJ
clinical trials
icotrokinra
psoriasis
In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen
Fierce Pharma
Thu, 05/8/25 - 10:56 pm
FDA
Richard Pazdur
Marty Makary
cancer
oncology
JNJ
Pfizer
Roche
Urogen
J&J survey finds pace of oncology innovation is overwhelming physicians
Fierce Pharma
Thu, 05/8/25 - 11:17 am
JNJ
oncology
oncologists
physicians
innovation
Amgen’s Stelara biosimilar gets off to fast start
BioPharma Dive
Sun, 05/4/25 - 12:00 pm
Amgen
Stelara
biosimilars
JNJ
J&J secures FDA OK for immune drug touted as future blockbuster
BioPharma Dive
Wed, 04/30/25 - 11:39 pm
JNJ
FDA
Imaavy
nipocalimab
myasthenia gravis
As J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defense
Fierce Pharma
Tue, 04/29/25 - 08:16 am
JNJ
TAR-200
bladder cancer
ImmunityBio
Trump’s tariff effect has dominated medtech earnings calls
Medtech Dive
Tue, 04/29/25 - 08:15 am
Medtech
earnings
JNJ
Abbott Labs
Boston Scientific
tariffs
Data readout puts J&J's bladder cancer drug back on track
Pharmaphorum
Tue, 04/22/25 - 11:00 am
JNJ
bladder cancer
TAR-200
clinical trials
J&J’s electrophysiology sales dip amid slow Varipulse start
Medtech Dive
Thu, 04/17/25 - 11:32 am
JNJ
Medtech
PFA
Medtronic
Boston Scientific
earnings
Varipulse
J&J CEO Duato Urges Tax Fix, Not Tariffs To Drive US Pharma Manufacturing
BioSpace
Tue, 04/15/25 - 07:55 pm
JNJ
Joaquin Duato
drug manufacturing
taxes
tariffs
Pharma CEOs
Johnson & Johnson Q1 2025 slides reveal strong growth across diversified portfolio
Investing.com
Tue, 04/15/25 - 11:25 am
JNJ
earnings

Pages